Neuland Laboratories Limited
NSE NEULANDLAB.NS
Neuland Laboratories Limited Current Liabilities for the year ending March 31, 2024: USD 51.27 M
Neuland Laboratories Limited Current Liabilities is USD 51.27 M for the year ending March 31, 2024, a -3.99% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
-
Neuland Laboratories Limited Current Liabilities for the year ending March 31, 2023 was USD 53.41 M, a 11.67% change year over year.
-
Neuland Laboratories Limited Current Liabilities for the year ending March 31, 2022 was USD 47.83 M, a -4.97% change year over year.
-
Neuland Laboratories Limited Current Liabilities for the year ending March 31, 2021 was USD 50.33 M, a 6.05% change year over year.
-
Neuland Laboratories Limited Current Liabilities for the year ending March 31, 2020 was USD 47.46 M, a 0.86% change year over year.
Key data
| Date | Current Liabilities | Total Non-Current Liabilities | Shareholders' Equity | Long-Term Debt |
|---|
Market news
Loading...
Don’t Miss A Beat
NSE: NEULANDLAB.NS
| CEO | Mr. Davuluri Sucheth Rao |
| IPO Date | Oct. 13, 2008 |
| Location | India |
| Headquarters | Phoenix IVY Building |
| Employees | 1,643 |
| Sector | Healthcare |
| Industries | |
Description
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.
Key trends
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email